
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1382752/publications.pdf Version: 2024-02-01



Ιμη Ζηγνο

#	Article	IF	CITATIONS
1	Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research, 1997, 25, 3389-3402.	6.5	64,420
2	Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	6.0	3,126
3	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . Science, 2011, 333, 1154-1157.	6.0	1,568
4	O 2 â‹â^' and H 2 O 2 -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell, 2017, 31, 487-500.e8.	7.7	316
5	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunology Research, 2019, 7, 630-643.	1.6	217
6	LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18892-18897.	3.3	157
7	HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Annals of Oncology, 2019, 30, 447-455.	0.6	151
8	EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. Journal of Thoracic Oncology, 2016, 11, 1718-1728.	0.5	118
9	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. Journal of Thoracic Oncology, 2015, 10, 778-783.	0.5	116
10	Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop. Molecular Therapy, 2019, 27, 1810-1824.	3.7	100
11	HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. British Journal of Cancer, 2014, 110, 1169-1178.	2.9	91
12	Cystatin M. Cancer Research, 2004, 64, 6957-6964.	0.4	83
13	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. Clinical Cancer Research, 2021, 27, 1296-1304.	3.2	79
14	Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene, 2004, 23, 2206-2215.	2.6	76
15	Targeting DNA Replication Stress for Cancer Therapy. Genes, 2016, 7, 51.	1.0	76
16	Ethanol alters cellular activation and CD14 partitioning in lipid rafts. Biochemical and Biophysical Research Communications, 2005, 332, 37-42.	1.0	73
17	Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles. Molecular Therapy, 2021, 29, 2931-2948.	3.7	58
18	Early detection of lung cancer by using an autoantibody panel in Chinese population. OncoImmunology, 2018, 7, e1384108.	2.1	54

#	Article	IF	CITATIONS
19	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. Clinical Lung Cancer, 2018, 19, e421-e430.	1.1	53
20	Advanced stage melanoma therapies: Detailing the present and exploring the future. Critical Reviews in Oncology/Hematology, 2019, 133, 99-111.	2.0	48
21	Identification of recurrent fusion genes across multiple cancer types. Scientific Reports, 2019, 9, 1074.	1.6	46
22	Metadherin enhances vulnerability of cancer cells to ferroptosis. Cell Death and Disease, 2019, 10, 682.	2.7	44
23	Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer, 2021, 21, 808.	1.1	43
24	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 2022, 11, 320.	1.8	43
25	FANCD2 and DNA Damage. International Journal of Molecular Sciences, 2017, 18, 1804.	1.8	42
26	Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. Molecular Cancer, 2019, 18, 85.	7.9	41
27	Targeting interleukin-1Î <sup>2</sup> and inflammation in lung cancer. Biomarker Research, 2022, 10, 5.	2.8	38
28	Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2021, 16, 237-249.	0.5	36
29	SBRT to adrenal metastases provides high local control with minimal toxicity. Advances in Radiation Oncology, 2017, 2, 581-587.	0.6	35
30	Soil physical characteristics of a degraded tropical grassland and a â€reforest': Implications for runoff generation. Geoderma, 2019, 333, 163-177.	2.3	35
31	LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated. Genes and Diseases, 2014, 1, 64-74.	1.5	34
32	EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1546-1552.	0.5	34
33	Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. Frontiers in Oncology, 2021, 11, 642110.	1.3	32
34	Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open, 2022, 7, 100395.	2.0	32
35	Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study. Clinical Lung Cancer, 2017, 18, 631-639.e2.	1.1	31
36	The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: Down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. Biochemical and Biophysical Research Communications, 2006, 340, 175-182.	1.0	27

#	Article	IF	CITATIONS
37	Harnessing DNA Replication Stress for Novel Cancer Therapy. Genes, 2020, 11, 990.	1.0	26
38	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics, 2017, 7, 4753-4762.	4.6	25
39	Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Scientific Reports, 2017, 7, 42979.	1.6	24
40	Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Research, 2017, 77, 3001-3012.	0.4	24
41	Mutated Fanconi anemia pathway in non-Fanconi anemia cancers. Oncotarget, 2015, 6, 20396-20403.	0.8	24
42	Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction. Journal of Hematology and Oncology, 2018, 11, 117.	6.9	23
43	OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S215-S216.	0.5	23
44	Targeting HER (ERBB) signaling in head and neck cancer: An essential update. Molecular Aspects of Medicine, 2015, 45, 74-86.	2.7	22
45	<p>Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China</p> . Cancer Management and Research, 2020, Volume 12, 6977-6985.	0.9	22
46	Prognostic significance of Daxx <scp>NCR</scp> (Nuclear/Cytoplasmic Ratio) in gastric cancer. Cancer Medicine, 2017, 6, 2063-2075.	1.3	21
47	Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. Clinical Cancer Research, 2018, 24, 858-869.	3.2	19
48	Runoff response and sediment yield of a landslide-affected fire-climax grassland micro-catchment (Leyte, the Philippines) before and after passage of typhoon Haiyan. Journal of Hydrology, 2018, 565, 524-537.	2.3	18
49	Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Acta Biochimica Et Biophysica Sinica, 2016, 48, 11-16.	0.9	17
50	Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. Journal of Thoracic Disease, 2018, 10, 5850-5859.	0.6	17
51	Effectiveness and safety of lowâ€dose apatinib in advanced gastric cancer: A realâ€world study. Cancer Medicine, 2020, 9, 5008-5014.	1.3	17
52	Endobronchial aspergilloma: A case report and literature review. Experimental and Therapeutic Medicine, 2017, 14, 547-554.	0.8	16
53	Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients. Oncotarget, 2017, 8, 62648-62657.	0.8	16
54	Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant. JAMA Oncology, 2022, 8, 1053.	3.4	16

#	Article	IF	CITATIONS
55	MTDH/AEC-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. Gynecologic Oncology, 2019, 155, 349-358.	0.6	15
56	Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. Gut Microbes, 2019, 10, 109-112.	4.3	15
57	Defined genetic events associated with the spontaneous in vitro transformation of ElA/Ras-expressing human IMR90 fibroblasts. Carcinogenesis, 2006, 27, 350-359.	1.3	14
58	DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis. Cell Death Discovery, 2021, 7, 169.	2.0	14
59	Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR. Lung Cancer, 2016, 94, 28-34.	0.9	12
60	Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer. Translational Oncology, 2017, 10, 132-141.	1.7	12
61	Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma. Npj Precision Oncology, 2021, 5, 6.	2.3	12
62	Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti–PD-L1 Immunotherapy Be Administered after Anti–PD-1–Related Immune Toxicities?. Journal of Thoracic Oncology, 2018, 13, e102-e103.	0.5	11
63	Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 10268.	1.8	11
64	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. Oncotarget, 2017, 8, 59008-59022.	0.8	11
65	Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. Journal of Immunotherapy, 2018, 41, 359-360.	1.2	10
66	Water budget and runâ€off response of a tropical multispecies "reforest―and effects of typhoon disturbance. Ecohydrology, 2019, 12, e2055.	1.1	10
67	Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC. Cancers, 2022, 14, 741.	1.7	10
68	ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers, 2019, 11, 718.	1.7	9
69	Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. Oncogene, 2021, 40, 1064-1076.	2.6	9
70	Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice. Annals of Translational Medicine, 2019, 7, 622-622.	0.7	9
71	Novel Expression of CST1 as Candidate Senescence Marker. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 723-731.	1.7	8
72	The Serum Level of IL-1B Correlates with the Activity of Chronic Pulmonary Aspergillosis. Canadian Respiratory Journal, 2018, 2018, 1-9.	0.8	8

#	Article	IF	CITATIONS
73	IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer. Journal of Hematology and Oncology, 2020, 13, 69.	6.9	8
74	Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. Redox Biology, 2022, 53, 102318.	3.9	8
75	Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response. Journal of Thoracic Oncology, 2018, 13, e183-e184.	0.5	7
76	Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion. Translational Lung Cancer Research, 2020, 9, 1452-1463.	1.3	7
77	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. Journal of Cancer, 2020, 11, 551-558.	1.2	7
78	Contribution of alternative splicing to breast cancer metastasis. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.5	7
79	Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, , .	1.3	4
80	Tuberculosis in umbilical cord blood transplant recipients: clinical characteristics and challenges. Bone Marrow Transplantation, 2015, 50, 465-468.	1.3	3
81	Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 7900.	1.8	3
82	Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alphaâ€Methylacylâ€Coenzyme A Racemase Gene Fusion Is Mediated by Mitogenâ€Activated Protein Kinase. Hepatology Communications, 2022, 6, 209-222.	2.0	3
83	P2.04-18 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S715.	0.5	2
84	Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer Journal of Clinical Oncology, 2021, 39, e21024-e21024.	0.8	2
85	DRAGoM: Classification and Quantification of Noncoding RNA in Metagenomic Data. Frontiers in Genetics, 2021, 12, 669495.	1.1	2
86	Abstract 3763: Ribonucleotide reductase subunit M2 plays important role in cisplatin resistance of cancer cells. Cancer Research, 2014, 74, 3763-3763.	0.4	2
87	Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110706.	1.4	2
88	OA03.04 Radiation Therapy Before Anti-PD1 Therapy Not Associated With Survival Difference in NSCLC; Single Institution Retrospective Review. Journal of Thoracic Oncology, 2017, 12, S1554.	0.5	1
89	OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure. Journal of Thoracic Oncology, 2018, 13, S349.	0.5	1
90	P2.12-02 Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology, 2018, 13, S791.	0.5	1

#	Article	IF	CITATIONS
91	Response to Erlotinib in aÂPatient with Compound EGFR L747S and Exon 19ÂDeletion. Journal of Thoracic Oncology, 2018, 13, e129-e130.	0.5	1
92	Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study Journal of Clinical Oncology, 2021, 39, TPS2678-TPS2678.	0.8	1
93	Targeting KRAS mutant non-small cell lung cancer (NSCLC) with deltarasin: A small molecule inhibitor of KRAS-PDEI´ interaction Journal of Clinical Oncology, 2015, 33, e13597-e13597.	0.8	1
94	Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status Journal of Clinical Oncology, 2014, 32, 2589-2589.	0.8	1
95	NEK2 as a prognostic marker and therapeutic target in adenocarcinoma of the lung Journal of Clinical Oncology, 2016, 34, e23282-e23282.	0.8	1
96	OA03.04 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S1132.	0.5	0
97	PR01.05 Racial Differences in Eligibility for Low Dose CT Screening and Burden of Metastatic Disease at Diagnosis of Lung Cancer in the United States. Journal of Thoracic Oncology, 2021, 16, S42.	0.5	0
98	OA05.08 Trends of Incidence and Burden of Metastatic Disease at Diagnosis of Lung Cancer after Implementation of Low Dose CT Screening in the United States. Journal of Thoracic Oncology, 2021, 16, S6-S7.	0.5	0
99	Abstract CT164: Pharmacological ascorbate enhances platinum-based chemotherapy responses in metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. , 2021, , .		0
100	Abstract 5383: The plasmonic photothermal therapy efficacy of Au NRsin vivousing a SCCHN xenograft mouse model. , 2014, , .		0
101	Abstract 4829: Evaluation prognostic significance of circulating tumor cells (CTCs) using multiplexed gold nanoparticles in patients with head and neck cancer. , 2014, , .		0
102	Abstract 20: Honokiol radiosensitizes squamous cells carcinoma of head and neck by down-regulation of survivin. , 2015, , .		0
103	Abstract 1428: Targeting RRM2 by siRNA inhibits cellular invasion and represents a rational approach for inhibition of metastasis of head and neck and lung cancers. , 2015, , .		0
104	Surgical management of pulmonary typical carcinoids: A population-based analysis Journal of Clinical Oncology, 2016, 34, 8540-8540.	0.8	0
105	Retrospective comparison between high-dose cisplatin and less-intensive weekly cisplatin/paclitaxel concurrently with radiation for locally advanced head and neck cancer (LAHNC) Journal of Clinical Oncology, 2016, 34, e17535-e17535.	0.8	0
106	Endobronchial aspergilloma: A case report and literature review. , 2016, , .		0
107	Abstract 2333: Modulation of Bax and mTOR for cancer therapeutics. , 2017, , .		0
108	Lung cancer liquid biopsy assays by qPCR using iDDS probe and Wild Terminator methods Journal of Clinical Oncology, 2018, 36, e21178-e21178.	0.8	0

#	Article	IF	CITATIONS
109	Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis By Affecting Vwf-Gpibα Interaction. Blood, 2018, 132, 1133-1133.	0.6	0
110	Abstract B24: The microbiome in lung cancer under immunotherapy: Significant compositional differences associated with treatment response and AEs. , 2020, , .		0

differences associated with treatment response and AEs. , 2020, , . 110